FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
 & Lead Plaintiff Deadline - January 16, 2018 - EconoTimes)
NEW YORK, Jan. 03, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Meridian Bioscience, Inc. ("Meridian Bioscience") (NASDAQ:VIVO) and certain of its officers, on behalf of a class who purchased Meridian securities between March 25, 2016 and July 13, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/vivo.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
The complaint alleges that throughout the class period Defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Defendant’s lead tests provide inaccurate results; and (2) consequently, Meridian’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/vivo or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Meridian you have until January 16, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]
